ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Jul 14, 2021 18:15 JST
Source:
NEC Corporation
NEC's artificial intelligence (AI) supports doctors to determine if colorectal lesions are potentially neoplastic
- CE marking-compliant software; soon available in Europe -
TOKYO, Jul 14, 2021 - (JCN Newswire) - NEC Corporation (NEC; TSE: 6701) announced today the development of an AI technology for supporting doctors in determining if colorectal lesions are neoplastic or non-neoplastic. NEC developed a new technology, called "Cx20," while seeking to assist in the early detection of colorectal lesions. Cx20 has already met the requirements for CE marking, a European safety, health and environmental protection standard, and will be integrated in the medical device AI diagnostic support software "WISE VISION Endoscopy" (1), with sales expected to start in Europe later this year.
The Cx20 function supports the identification of disease. During examinations, suspected lesions are automatically detected through video taken by endoscope devices. Doctors then extract still images (left) and analysis results are soon displayed (right)
This software connects and interacts with existing endoscopic equipment and automatically notifies users if a lesion is possibly neoplastic based on images captured during endoscopy procedures. The software then becomes an extra tool immediately available to assist endoscopists in the differentiation of lesions and reduces the burden on patients.
Colorectal cancer originates from precancerous lesions (colorectal neoplastic polyps) and it is possible to suppress its progression by detecting and removing lesions at an early stage during endoscopy procedures. It is, however, sometimes difficult for endoscopists to visually distinguish between neoplastic and non-neoplastic lesions during endoscopy examinations, resulting in unnecessary biopsies and removal of non-neoplastic lesions, thereby causing additional stress and discomfort to patients. Colorectal cancer is said to be the second-largest cancer (2) in the European region, and the latest version of WISE VISION Endoscopy, which launches first in Europe, promises to help doctors address this challenging issue.
To improve the chances of identifying if colorectal lesions are possibly neoplastic, and so to help endoscopists in their decision process, NEC developed a new technology where the learning power of AI is used to combine information of endoscopy images and data from the findings of expert physicians. Specifically, the technology analyzes still images of lesions taken with endoscopy devices, and if the AI determines that a colorectal lesion is likely to be neoplastic a "High possibility" notification message is displayed.
NEC and the National Cancer Center Japan have been collaborating since 2016 to develop a technology that automatically detects suspected colorectal lesions during endoscopy examinations. NEC began sales of software incorporating this technology in January of this year (3). With the addition of this function in Europe, WISE VISION Endoscopy aims to help reduce the burden on doctors and patients by providing additional and immediately beneficial support during the examination process. In developing this solution NEC applied its face recognition technology, belonging to its portfolio of cutting edge AI based technologies (labelled "NEC the WISE"), which has been highly evaluated by the National Institute of Standards and Technology (NIST) in the United States (4).
In the future, NEC will further promote joint research with the National Cancer Center Japan to further enhance the performance of its AI technology and to assist endoscopists with its usage.
About WISE VISION Endoscopy
This software can be connected to endoscopes from leading endoscope manufacturers (5). By simply connecting an existing endoscope to a monitor and terminal equipped with the software, users can start using it immediately. The system issues sound notifications when a candidate lesion has been located, and the type and volume of the notification can be customized at any time according to user preferences. Moreover, a highly visible user interface allows intuitive operation, enabling endoscopists to smoothly proceed with examinations.
Going forward, NEC aims to accelerate digital transformation in the medical field by providing safe and secure products and services, including AI, to promote a healthy, and sustainable society, where individuals can thrive from the utilization of advanced IT technologies.
(1) "WISE VISION" is a registered trademark of NEC Corporation in the United States of America, the European Union and the United Kingdom.
(2) According to United European Gastroenterology
new window
https://ueg.eu/p/78#
(3) NEC releases "WISE VISION Endoscopy" in Europe and Japan
https://www.nec.com/en/press/202101/global_20210112_01.html
Yamada M, Saito Y, Imaoka H, et al. Development of a real-time endoscopic image diagnosis support system using deep learning technology in colonoscopy. Sci Rep. 2019;9:14465. doi: 10.1038/s41598-019-50567-5. PMID: 31594962
(4) NEC Face Recognition Technology Ranks First in NIST Accuracy Testing
https://www.nec.com/en/press/201910/global_20191003_01.html
(5) Connectivity and operations have been confirmed with the following endoscopes.
Olympus EVIS LUCERA ELITE Video System Center CV-290
FUJIFILM ELUXEO video processor VP-7000
Source: NEC Corporation
Sectors: Artificial Intel [AI], MedTech
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Fujitsu SX Survey reveals key success factors for sustainability
Apr 23, 2024 10:25 JST
Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions
Apr 22, 2024 16:09 JST
NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II
Apr 22, 2024 15:09 JST
Soft Space Launches the First and Only JCB Payment Gateway in Malaysia
Apr 22, 2024 15:00 JST
TOYOTA GAZOO Racing takes a one-two in Croatian thriller
Apr 22, 2024 10:47 JST
First-ever Mazda CX-80 Crossover SUV Unveiled in Europe
Apr 19, 2024 13:50 JST
Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces
Apr 19, 2024 10:17 JST
Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas
Apr 18, 2024 17:01 JST
Toyota Launches All-New Land Cruiser "250" Series in Japan
Apr 18, 2024 13:39 JST
Fujitsu and Oracle collaborate to deliver sovereign cloud and AI capabilities in Japan
Apr 18, 2024 11:14 JST
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Apr 18, 2024 10:53 JST
All-New Triton Confirmed as First Double-Cab Pickup Truck to Achieve 2024 Five-Star ANCAP Safety Rating
Apr 18, 2024 09:22 JST
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
Apr 17, 2024 16:17 JST
Honda Unveils Next-generation EV Series for China
Apr 17, 2024 12:15 JST
Lexus presents Time at the 2024 Milan Design Week
Apr 16, 2024 18:49 JST
Mitsubishi Corporation Announces Participation in a DAC Project in Louisiana, USA
Apr 16, 2024 14:36 JST
New circuit challenge for TOYOTA GAZOO Racing
Apr 15, 2024 17:21 JST
TOYOTA GAZOO Racing back on asphalt for Croatian challenge
Apr 12, 2024 19:36 JST
Heidelberg Materials North America Announces Latest Milestone in Edmonton CCUS Project
Apr 12, 2024 14:39 JST
MHIAEL Completes Expansion of the its Nagasaki Plant for Manufacture of Aero Engine Combustors
Apr 11, 2024 18:08 JST
More Latest Release >>
Related Release
NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II
4/22/2024 3:09:00 PM JST
DOCOMO, NTT, NEC and Fujitsu Develop Top-level Sub-terahertz 6G Device Capable of Ultra-high-speed 100 Gbps Transmission
4/11/2024 3:10:00 PM JST
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
4/10/2024 1:36:00 PM JST
NEC white paper proposes comprehensive process workflow for the application of AI-driven personalized cancer vaccines
4/8/2024 1:45:00 PM JST
NEC develops marketing strategy planning & effectiveness simulation technology using generative AI
3/25/2024 10:08:00 AM JST
NEC and NTT successfully conduct first-of-its-kind long-distance transmission experiment over 7,000km using 12-core optical fiber
3/22/2024 8:38:00 AM JST
NEC and Tokyo Medical and Dental University use AI to assist self-care for chronic lower back pain
3/21/2024 10:02:00 AM JST
NEC and Skyloom to Pioneer 100 Gbps Space Optical Communications, Transforming Global Internet Connectivity
3/20/2024 3:30:00 PM JST
NEC named to list of Top 100 Global Innovators by Clarivate for 13th consecutive year
3/7/2024 11:24:00 AM JST
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
3/5/2024 9:05:00 AM JST
More Press release >>